Clinical Trial Update: Activated T Lymphocytes Expressing CARs, Relapsed CD19+ Malignancies Post-Allo HSCT(CARPASCIO) [Phase 1]

View source ↗

Summary

Phase 1 trial update of CAR T cells (CARPASCIO) targeting CD19 in relapsed CD19+ malignancies after allogeneic HSCT. The study is currently active but not recru…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• B-cell Acute Lymphoblastic Leukemia
• B-cell Chronic Lymphocytic Leukemia
• Non-hodgkin Lymphoma

Drugs mentioned

• CARPASCIO (CD19-directed chimeric antigen receptor T-cell therapy)

Snippet

Sponsor: Baylor College of Medicine | Conditions: Non-Hodgkin's Lymphoma, B-Cell ALL | Phase 1 | Status: ACTIVE_NOT_RECRUITING